Yang Xu | Mount Sinai

About Me

Yang Xu is a current PhD student in the Development Regeneration and Stem Cells (DRS) training area at the Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai. Yang Xu is a member of Kovacic Lab where he focuses on cardiovascular diseases based on mouse and pig models as well as human samples. He is especially interested in the role of endothelial-to-mesenchymal transition (EndMT) in atherosclerosis. Yang Xu's research is aiming at dissecting the biological process of EndMT in atherosclerosis and its relationship with endothelial regeneration, which is important in preventing and treating vessel plaques. Yang Xu received his medical degree from Capital Medical University (China) in 2016 and Masters of Science degree from Mount Sinai in 2018.

Language

English

Research Topics

Bioinformatics, Cardiovascular, Cell Adhesion, Cell Biology, Cell Transformation, Differentiation, Endothelial Cells, Epigenetics

Multi-Disciplinary Training Areas

Development Regeneration and Stem Cells [DRS]

Education

MBBS, Capital Medical University

Master of Science, Icahn School of Medicine at Mount Sinai

Locations

Hess CSM Building Floor 7th floor, Box 1030 Room 302, 1470 Madison Ave, New York, NY, 10029

212-824-9022

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. XU has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.